ClinicalTrials.gg
RecruitingNCT07613710Updated Aug 12, 2026

A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy

A Phase 1 interventional study of Lu AH69593 and Placebo in Narcolepsy, sponsored by H. Lundbeck A/S. Recruiting at 2 sites in Finland. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jun 2025, registered May 2026).
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies in Narcolepsy with a site in Finland — 3 open to participants now, 3 under way, 2 of them phase 3. Narcolepsy · Finland.

Planned enrollment
9th of 14
104 · median 108
Started
2025
the only one that year
Phase 1
2 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
H. Lundbeck A/S

Among the 14 studies in Narcolepsy with a site in Finland, this one is the 9th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 1, and was the 14th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

3 of the 14 studies in Narcolepsy with a site in Finland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Narcolepsy with a site in Finland, or all of them as a file.
02

Study summary

The purpose of the trial is to determine if Lu AH69593 is safe and well tolerated. The trial will also look at how the body processes Lu AH69593 with and without food.

03

Conditions studied

  • Narcolepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

For all participants in any trial Part (A, B, C and D):

  • The participant has a resting supine pulse ≥45 and ≤100 beats per minute (bpm) at the Screening Visit and at the Baseline Visit.

Specifically for participants in trial Part A, B, and D:

  • The participant has a (BMI) ≥18.5 and ≤30 kilograms (kg)/square meter (m\^2) at the Screening Visit.
  • The participant has a normal circadian rhythm, defined as a person who usually wakes up between 6:00 and 9:00 a.m. and goes to sleep between 9:00 p.m. and midnight.
  • The participant is ≥18 and ≤55 years of age at the Screening Visit.

Specifically for participants in trial Part C:

  • The participant has a BMI ≥18.5 and ≤35 kg/m\^2 at the Screening Visit.
  • The participant has NT1, diagnosed according to International Classification of Sleep Disorders, 3rd edition criteria, with a history of disease diagnosis >3 months prior to the Screening Visit.
  • The participant is ≥18 and ≤64 years of age at the Screening Visit.

Key Exclusion Criteria:

For all participants in any trial Part (A, B, C and D):

  • The participant has previously been enrolled in this trial.
  • The participant has previously been dosed with Lu AH69593.
  • The participant has participated in a clinical trial \<30 days prior to the Screening Visit.
  • The participant is pregnant, breastfeeding, intends to become pregnant, or is of and not willing to use adequate methods.
  • The participant has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia, that has not been in remission for >5 years prior to the first dose of medicinal product (IMP).
  • The participant has worked shifts, including night duty, or has travelled across >3 time zones \<2 weeks prior to the first dose of IMP.
  • The participant trains/exercises intensively, for example, for a marathon or triathlon, or at a competitive level.

Specifically for participants in trial Part A, B and D:

  • The participant has had a illness from which he/she recovered \<4 weeks prior to the first dose of IMP.

Specifically for Participants in trial Part B and C:

  • The participant is at significant risk of suicide based on medical history, mental status, investigator judgement, or the C-SSRS answer of 'yes' to suicidal ideation question 4 or 5 or 'yes' to suicidal behaviour, within the last 6 months on the C-SSRS at the Screening Visit or 'Since last visit' at the Baseline Visit Day -1.

Specifically for participants in trial Part C:

  • The participant has any other disorder for which the treatment takes priority over treatment of narcolepsy or is likely to interfere with trial treatment or impair treatment compliance.
  • The participant has a current medical disorder, other than NT1, associated with excessive daytime sleepiness (EDS).

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    Part A (Single Ascending Dose [SAD] in Healthy Participants): Lu AH69593 or Placebo

    Participants will receive single oral dose of Lu AH69593 or placebo.

    Drug: Lu AH69593 · Drug: Placebo

  • Experimental
    Part B (Multiple Ascending Dose [MAD] in Healthy Participants): Lu AH69593 or Placebo

    Participants will receive Lu AH69593 or placebo orally for 10 days.

    Drug: Lu AH69593 · Drug: Placebo

  • Experimental
    Part C (MAD in Participants With Narcolepsy Type 1 [NT1]): Lu AH69593

    Participants will receive Lu AH69593 orally for 84 days.

    Drug: Lu AH69593

  • Experimental
    Part D (Food Effect in Healthy Participants): Lu AH69593

    Participants with receive two single oral doses of Lu AH69593 in fasting or fed condition.

    Drug: Lu AH69593

Interventions

  • DrugLu AH69593

    Lu AH69593 will be administered per schedule specified in the arm description.

  • DrugPlacebo

    Placebo will be administered per schedule specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline up to Day 90

  2. Bond Lader Visual Analogue Scale (VAS) dimension scores (Alertness, Contentedness, and Calmness)

    Time frame: Baseline up to Day 84

  3. Psychomotor Vigilance Task (PVT) Parameter - Change From Baseline in Reaction Time to Stimuli

    Time frame: Baseline, up to Day 11

  4. PVT Parameter - Change From Baseline in Number of Errors of Omission

    Time frame: Baseline, up to Day 11

  5. PVT Parameter - Change From Baseline in Number of Errors of Commission (Response Without Stimulus)

    Time frame: Baseline, up to Day 11

  6. Number of Participants With Suicidal Ideation and Behaviour Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Baseline up to Day 90

  7. Area Under the Curve (AUC) From Zero to Time of Last Quantifiable Concentration (AUC0-t) of Lu AH69593

    Time frame: Up to 84 days

  8. Maximum Observed Plasma Concentration (Cmax) of Lu AH69593

    Time frame: Up to 84 days

  9. Time to Reach Cmax (Tmax) of Lu AH69593

    Time frame: Up to 84 days

  10. AUC From Time Zero to Infinity (AUC0-inf)

    Time frame: Up to 6 days

07

Study locations

1 of 2 sites recruiting
  • Terveystalo Helsinki, Sleep Clinic
    Helsinki, 00380, Finland
    Recruiting
  • CRST, Clinical Research Services Turku
    Turku, 20520, Finland
    Completed

    Not enrolling at this site.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.

Of 13 phase 1 interventional studies under Narcolepsy, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's planned 19 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 29, 2026
StartActual
Jun 13, 2025
Primary completionEst.
Feb 9, 2027
CompletionEst.
Feb 16, 2027
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07613710
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 13, 2025
Primary completion
Feb 9, 2027 (estimated)
Completion
Feb 16, 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Email contact via H. Lundbeck A/S
Contact
HQ_Medinfo@Lundbeck.com
+45 36301311
Email contact via H. Lundbeck A/S
study director · H. Lundbeck A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion